OpenLB
Open Library of Bioscience
Advanced Search

Journal

Publication Year

1 year 3 years 5 years 10 years
2021 - 2032
202120222023
202420252026
202720282029
203020312032
2021 - 2032
202120222023
202420252026
202720282029
203020312032

Publication Type

Associated Data

Found 965 results

Filters: Cabotegravir

Cabotegravir: The first long-acting injectable for HIV pre-exposure prophylaxis.
Caitlin Prather, Chaeok Jeon
Am J Health Syst Pharm. 10 21, 2022.79(21):1898-1905 Print
Source:PubMed
PMID: 35894204 doi:10.1093/ajhp/zxac201
Cabotegravir long-acting for HIV-1 prevention.
Chasity D Andrews, Walid Heneine
Curr Opin HIV AIDS. Jul, 2015.10(4):258-63 Print
Source:PubMed
PMID: 26049951 doi:10.1097/COH.0000000000000161
A literature review of the patent application publications on cabotegravir - an HIV integrase strand transfer inhibitor.
Lidija Kovač, Zdenko Časar
Expert Opin Ther Pat. Mar, 2020.30(3):195-208 Print-Electronic
Source:PubMed
PMID: 31944142 doi:10.1080/13543776.2020.1717470
A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV.
Sara H Bares, Kimberly K Scarsi
Curr Opin HIV AIDS. 01 01, 2022.17(1):22-31 Print
Source:PubMed
PMID: 34871188 doi:10.1097/COH.0000000000000708
Cabotegravir: a novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection.
John D Zeuli, Christina G Rivera, Bradley L Smith, Ashley Otto, Zelalem Temesgen
Drugs Today (Barc). Dec, 2022.58(12):555-576 Print
Source:PubMed
PMID: 36651065 doi:10.1358/dot.2022.58.12.3448340
Understanding of cabotegravir degradation through isolation and characterization of key degradation products and kinetic studies.
Lidija Kovač, Martin Črnugelj, Robert Roškar, Tina Trdan Lušin, Zdenko Časar
J Pharm Biomed Anal. Jul 15, 2021.201:114096 Print-Electronic
Source:PubMed
PMID: 33957367 doi:10.1016/j.jpba.2021.114096
Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV.
Elahe Taki, Faezeh Soleimani, Arezoo Asadi, Hossein Ghahramanpour, Ali Namvar, Mohsen Heidary
Expert Rev Anti Infect Ther. 08, 2022.20(8):1135-1147 Print-Electronic
Source:PubMed
PMID: 35596583 doi:10.1080/14787210.2022.2081153
Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV.
Paul Thoueille, Susana Alves Saldanha, Fabian Schaller, Eva Choong, Fran��ois Veuve, Aline Munting, Matthias Cavassini, Dominique Braun, Huldrych F G��nthard, Jessy J Duran Ramirez, Bernard Surial, Hansjakob Furrer, Andri Rauch, Pilar Ustero, Alexandra Calmy, Marcel St��ckle, Caroline Di Benedetto, Enos Bernasconi, Patrick Schmid, Catia Marzolini, Fran��ois R Girardin, Thierry Buclin, Laurent A Decosterd, Monia Guidi, Swiss HIV Cohort Study
Clin Pharmacol Ther. Jun, 2024.115(6):1450-1459 Print-Electronic
Source:PubMed
PMID: 38519844 doi:10.1002/cpt.3240
Long-acting antiretroviral therapy in the context of viral suppression.
Kyle Ring, Chloe Orkin
Curr Opin HIV AIDS. Jan 01, 2025.20(1):4-10 Print-Electronic
Source:PubMed
PMID: 39633535 doi:10.1097/COH.0000000000000897
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
Miranda I Murray, Martin Markowitz, Ian Frank, Robert M Grant, Kenneth H Mayer, Krischan J Hudson, Britt S Stancil, Susan L Ford, Parul Patel, Alex R Rinehart, William R Spreen, David A Margolis
HIV Clin Trials. 08, 2018.19(4):129-138 Print-Electronic
Source:PubMed
PMID: 30445896 doi:10.1080/15284336.2018.1511346
0